巴利昔单抗和抗胸腺细胞球蛋白在肾移植免疫诱导中有效性和安全性的Meta分析  

Efficacy and safety of basiliximab and antithymocyte globulin in immune induction in kidney transplantation:a Meta-analysis

作　　者：何跃[1,2] 郑瑾 李杨[2] 田晓辉[2] 田普训[2] 丁小明[2] 薛武军[2] 康永明[1] 奉友刚[1] He Yue;Zheng Jin;Li Yang;Tian Xiaohui;Tian Puxun;Ding Xiaoming;Xue Wujun;Kang Yongming;Feng Yougang(Department of Urology,Suining Central Hospital,Suining 629000,China;不详)

机构地区：[1]遂宁市中心医院泌尿外科,四川遂宁629000 [2]西安交通大学第一附属医院肾病医院肾移植科

出　　处：《器官移植》2022年第4期495-502,共8页Organ Transplantation

基　　金：国家自然科学基金面上项目(82170768)。

摘　　要：目的通过系统评价和Meta分析评估巴利昔单抗(BAS)和抗胸腺细胞球蛋白(ATG)在肾移植免疫诱导治疗中的有效性和安全性。方法系统检索国内外数据库,筛选比较BAS和ATG在肾移植免疫诱导治疗中的前瞻性随机对照临床研究文献。采用Jadad评分量表对文献质量评价并提取数据。分析BAS和ATG对肾移植术后1年急性排斥反应发生率、移植肾存活率、受者生存率、移植肾功能延迟恢复发生率、感染率、巨细胞病毒感染率、恶性肿瘤发生率、白细胞和血小板减少发生率的影响。结果纳入10篇英文文献,共1721例肾移植受者,其中883例使用ATG,838例使用BAS。ATG组和BAS组术后1年急性排斥反应发生率、移植肾存活率、受者生存率、移植肾功能延迟恢复发生率、感染率、巨细胞病毒感染率和血小板减少发生率的差异均无统计学意义(均为P>0.05)。ATG组术后1年内恶性肿瘤发生率、白细胞减少发生率均高于BAS组,差异均有统计学意义(均为P<0.05)。结论使用ATG和BAS进行肾移植免疫诱导治疗,其术后1年有效性相当,但BAS安全性较好。未来应进行不同的免疫风险分层的临床研究,以达到个体化精准治疗。Objective To evaluate the efficacy and safety of basiliximab(BAS)and antithymocyte globulin(ATG in immune induction therapy in kidney transplantation by systematic review and Meta-analysis.Methods Prospective randomized controlled clinical trials screening and comparing BAS and ATG in immune induction therapy in kidney transplantation were systematically searched from global databases,screened and compared.The quality of clinical trials was evaluated by Jadad scoring system and data extraction was performed.The effects of BAS and ATG on the incidence of acute rejection,survival rate of kidney allografts,survival rate of recipients,incidence of delayed graft function,infection,cytomegalovirus infection,malignant tumor,leukopenia and thrombocytopenia at 1 year after kidney transplantation were analyzed.Results A total of 10 clinical trials in English consisting of 1721 kidney transplant recipients were searched,including 883 cases in the ATG group and 838 cases in the BAS group.No significant differences were observed in the incidence of acute rejection,survival rate of kidney allografts,survival rate of recipients,incidence of delayed graft function,infection,cytomegalovirus infection and thrombocytopenia at postoperative 1 year between the ATG and BAS groups(all P>0.05).The incidence of malignant tumor and leukopenia at postoperative 1 year in the ATG group were significantly higher than those in the BAS group(both P<0.05).Conclusions The use of ATG and BAS for immune induction therapy in kidney transplantation yield equivalent efficacy at postoperative 1 year,but BAS is safer than ATG.Clinical trials related to stratified analyses of immune risk are urgently required to achieve individualized precision treatment.

关 键 词：巴利昔单抗 抗胸腺细胞球蛋白 肾移植 免疫诱导 排斥反应 移植肾功能延迟恢复 感染 巨细胞病毒 

分 类 号：R617[医药卫生—外科学] R392.4[医药卫生—临床医学]